Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U6 small nuclear 1316, pseudogene (RNU6-1316P) is a pseudogene corresponding to the U6 small nuclear RNA (snRNA), a crucial component of the spliceosomal machinery responsible for the removal of introns from pre-mRNA in eukaryotic cells[1][5]. Pseudogenes like RNU6-1316P are nonfunctional genomic elements typically derived from duplication or retrotransposition events of functional genes or RNAs, and they usually lack protein-coding potential or direct biological function[3][4]. Although a minority of pseudogenes can exert regulatory effects—such as acting as competitive endogenous RNAs (ceRNAs) or producing small RNAs that influence gene regulation—most, including RNU6-1316P, do not fulfill the criteria of therapeutic targets, receptors, enzymes, or transporters[4]. There is no evidence implicating RNU6-1316P in human disease, drug interactions, therapeutic mechanisms, use as a biomarker, or safety concerns. The canonical, functional form of U6 snRNA participates directly in spliceosome activity[1][5], but its pseudogenes, including RNU6-1316P, are not known to retain such functions[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 1316, pseudogene (RNU6-1316P).